Jason Fontenot
Net worth: 68 544 $ as of 2024-04-29
Profile
Jason D.
Fontenot worked as the Chief Scientific Officer & Senior Vice President at Sangamo Therapeutics, Inc. from 2021 to 2024.
Prior to that, he was the Chief Scientific Officer at Immusoft Corp.
from 2018 to 2019 and the Head-Exploratory Research at Juno Therapeutics, Inc. from 2016 to 2018.
He earned a doctorate degree from the University of Washington.
Known holdings in public companies
| Company | Date | Number of shares | Valuation | Valuation date |
|---|---|---|---|---|
| 2023-11-24 | 136,270 ( 0.07% ) | 68 544 $ | 2024-04-29 |
Former positions of Jason Fontenot
| Companies | Position | End |
|---|---|---|
| SANGAMO THERAPEUTICS, INC. | Chief Tech/Sci/R&D Officer | 2024-01-01 |
Immusoft Corp.
 Immusoft Corp. Medical/Nursing ServicesHealth Services Immusoft Corp. provides disease curing services through immune cells. The firm offers ISP, gene delivery technology and lymphopoiesis culture system. The company was founded by Matthew Scholz in 2009 and is headquartered in Seattle, WA. | Chief Tech/Sci/R&D Officer | 2019-02-28 |
| JUNO THERAPEUTICS INC | Chief Tech/Sci/R&D Officer | 2017-12-31 |
Training of Jason Fontenot
| University of Washington | Doctorate Degree |
Experiences
Positions held
Connections
1st degree connections
1st degree companies
Male
Female
Members of the board
Executives
Linked companies
| Listed companies | 1 |
|---|---|
| SANGAMO THERAPEUTICS, INC. | Health Technology |
| Private companies | 2 |
|---|---|
Immusoft Corp.
Immusoft Corp. Medical/Nursing ServicesHealth Services Immusoft Corp. provides disease curing services through immune cells. The firm offers ISP, gene delivery technology and lymphopoiesis culture system. The company was founded by Matthew Scholz in 2009 and is headquartered in Seattle, WA. | Health Services |
Juno Therapeutics, Inc.
 Juno Therapeutics, Inc. BiotechnologyHealth Technology Juno Therapeutics, Inc. is a biopharmaceutical company, which engages in the development of innovative cellular immunotherapy for the treatment of cancer. It offers platforms which includes chimeric antigen receptors and T-cell receptors. The company was founded by Hans Edgar Bishop, Lawrence Corey, Richard D. Klausner, Stan Riddell, Isabelle Riviere, and Robert Taylor Nelsen on August 5, 2013 and is headquartered in Seattle, WA. | Health Technology |
- Stock Market
- Insiders
- Jason Fontenot
